G Faghihi; N Ghanei; P Rajabi; D Taheri
Volume 7, Issue 3 , 2004, , Pages 145-151
Abstract
Background: P53 tumor suppressor gene mutation is one of the most common genetic alterations in human malignancies. The mutated from of the gene is stable and can be detected with immunohistochemistry methods. There is much controversy about the expression rate of this gene in malignant melanoma. Objective: ...
Read More
Background: P53 tumor suppressor gene mutation is one of the most common genetic alterations in human malignancies. The mutated from of the gene is stable and can be detected with immunohistochemistry methods. There is much controversy about the expression rate of this gene in malignant melanoma. Objective: To determine the frequency of the P53 antigen expression by sex, age, type and thickness of melanoma, and site of the antigen expression. Patients and methods: Paraffin embedded blocks of 50 patients (45 primary and 5 metastatic) with documented diagnosis of melanoma were deparaffinized and immunostained with D0-7 monoclonal antibody. The lesions were divided depending on the degree of the staining as follows: 1) (No staining), 2) Mild (Less than 10%), 3) Moderate (10%-50%), 4) Severe (More than 50%). Results: Of 50 cases, 27 (54%) evaluated skin biopsy specimens belonged to female patients and 23 (46%) skin biopsies were related to male patients. 40% of lesions were graded as no staining. 36% of lesions showed mild staining, 14% moderate and 10% severe staining. Site of expression was exclusively in the cytoplasm. There was no meaningful statistical relationship between severity of staining and the age group, and sex of the patients, type and thickness of melanoma (P>0.05). Conclusion: Mutation in P53 tumor suppressor gene probably occurs in the early stages of melanoma.
A Asilian; A Momeni; G Faghihi; V Sadeghi; M Sadeghi; H Sadeghi
Volume 6, Issue 2 , 2003, , Pages 30-33
Abstract
Background: Cutaneous leishmaniasis (CL) is a parasitic disease caused by leishmania species. An ideal treatment for CL has not found yet. Objectives: To evaluate the efficacy of cryotherapy alone and combined with intralesional glucantime injection in the treatment of papulonodular CL. Patients and ...
Read More
Background: Cutaneous leishmaniasis (CL) is a parasitic disease caused by leishmania species. An ideal treatment for CL has not found yet. Objectives: To evaluate the efficacy of cryotherapy alone and combined with intralesional glucantime injection in the treatment of papulonodular CL. Patients and Methods: 300 patients with CL were randomly assigned to two treatment groups in this clinical trial. In group 1, 100 patients with 149 lesions were treated with cryotherapy plus intralesional glucantime injection every 2 weeks. In group 2, 200 patients with 230 lesions were treated only with cryotherapy, every 2 weeks. Both groups were followed for 6 months after last treatment. Results: Clinical and parasitological cure were seen in 90% of cases in group 1 and 57.3% in group 2 (P<0.05). Conclusion: Combination of cryotherapy and intralesional glucantime injection is an effective treatment modality in early lesions of CL.